RxSight

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded by Robert Grubbs and Daniel Schwartz on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RxSight posts stellar Q4 results, eyes strong growth in 2023

RxSight's Q4 2022 performance reflects robust revenue growth, improved gross margin, and strategic financial management. The company's focus on expanding LDD installations and LAL sales sets a positive trajectory for future growth.
While challenges such as net losses and operating expenses persist, RxSight's strong cash position and revenue guidance for 2023 indicate resilience and potential for sustained growth. Leveraging opportunities in market expansion and product innovation will be key for RxSight's future success.

RxSight reports stellar Q1 revenue growth, eyes profitability challenges

RxSight demonstrated robust revenue growth and a strong cash position in Q1 2023, while facing challenges with profitability and escalating operating expenses. The company's increased revenue guidance and positive market feedback present opportunities for future growth through product adoption and market expansion.

RxSight reports stellar Q2 results, raises guidance amid strategic focus

RxSight's Q2 2023 performance reflects robust revenue growth and margin improvement, supported by strong LAL sales. While challenges like net losses persist, the company's strategic focus on technology and market growth presents promising opportunities for future success.

RxSight reports stellar Q3 results, eyes profitability and product expansion

RxSight's Q3 performance reflects robust revenue growth, driven by strong LAL sales and operational efficiency improvements, positioning the company for future success.
With a focus on innovation and product efficacy, RxSight's strategic strengths lie in their ability to meet market demand and drive revenue through expanded offerings.
While challenges in managing expenses and sustaining growth persist, RxSight's financial strength and market opportunities signal a promising outlook for profitability and value creation.

RxSight reports strong revenue growth driven by LAL sales

RxSight's Q4 2023 performance showcased robust revenue growth driven by LAL sales, despite increased operating expenses and a net loss.
The company's strong cash position, debt-free status, and focus on innovation position it well for future revenue growth and market expansion.
Challenges include managing expenses, navigating complex international markets, and optimizing product mix for sustained profitability.
Opportunities lie in European market expansion, investor engagement, and leveraging technology to drive adoption and revenue growth.

RxSight reports robust Q1 revenue growth, faces expense challenges

RxSight's Q1 2024 performance reflects strong revenue growth and improved gross margin, yet challenges persist with increasing expenses and net loss.
The company's focus on LAL technology, guidance increase, and market expansion efforts present opportunities for future growth and market penetration.
To address challenges, RxSight needs to balance cost management with innovation and capitalize on opportunities in adoption trends and international markets.

RxSight reports robust Q2 earnings, eyes international expansion for growth

RxSight's Q2 performance reflects strong revenue growth, improved margins, and strategic investments in growth areas.
While facing rising expenses, RxSight's focus on premium products, international expansion, and innovation positions it for future success.
Challenges in cost management and market dynamics require careful navigation, but opportunities in product expansion and market penetration are promising.
Overall, RxSight's financial outlook remains positive, supported by a strong cash position and a clear growth strategy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

RxSight, Inc. (NASDAQ:RXST ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Ron Kurtz - President and Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG David Saxon - Needham Company Operator Good day, ladies and gentlemen and welcome to the RxSight, Inc. First Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Philip Taylor.

RxSight, Inc. (RXST) CEO Ron Kurtz on Q1 2022 Results - Earnings Call Transcript

ALISO VIEJO, Calif. , April 19, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that its Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various surgeon presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Washington D.C. on April 22-26, 2022.

Surgeon Presentations to Highlight RxSight® Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

ALISO VIEJO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming Needham Virtual Healthcare Conference.

RxSight, Inc. to Present at the Needham Virtual Healthcare Conference

RxSight, Inc. (RXST) CEO Ron Kurtz on Q4 2021 Results - Earnings Call Transcript

ALISO VIEJO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months and fiscal year ended December 31, 2021.

RxSight, Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results

ALISO VIEJO, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the fourth quarter and fiscal year 2021 after the market close on Tuesday, March 8, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight, Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 8, 2022

ALISO VIEJO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming virtual SVB Leerink Global Healthcare Conference.

RxSight, Inc. to Present at the SVB Leerink Global Healthcare Conference

The stock price of RxSight Inc (NASDAQ: RXST) increased by 28.21% today. This is why it happened.

RxSight Stock (RXST): Why The Price Surged Today

ALISO VIEJO, Calif., Jan. 09, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced preliminary unaudited financial and operational results for the fourth quarter and fiscal year 2021.

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results

ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors.

RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D.

ALISO VIEJO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming virtual J.P. Morgan Healthcare Conference.

RxSight to Present at the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming virtual Ophthalmology Day at BTIG.

RxSight to Participate in the Ophthalmology Day at BTIG

RxSight, Inc. (RXST) CEO Ron Kurtz On Q3 2021 Results - Earnings Call Transcript

ALISO VIEJO, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the third quarter of 2021 after the market close on Wednesday, November 10, 2021. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight to Report Third Quarter 2021 Financial Results on November 10, 2021

ALISO VIEJO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended June 30, 2021.

RxSight Reports Second Quarter 2021 Financial Results

ALISO VIEJO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ: RXST) an ophthalmic medical device company, today announced an updated date for reporting second quarter 2021 financial results. In observance of the Rosh Hashanah holiday, the company will now report after the market close on Thursday, September 9, 2021. Management will discuss the results during a conference call beginning that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight Announces Updated Date for Reporting Second Quarter 2021 Financial Results on September 9, 2021

ALISO VIEJO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company, today announced plans to participate in the upcoming virtual Wells Fargo Healthcare Conference.

RxSight to Participate in the Wells Fargo Healthcare Conference

RxSight has commercialized the first and only FDA approved customizable intraocular lens.

RxSight: First And Only Customizable Intraocular Lens

ALISO VIEJO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced that it will report financial results for the second quarter of 2021 after the market close on Tuesday, September 7, 2021. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

RxSight to Report Second Quarter 2021 Financial Results on September 7, 2021

Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTech company, went public in late July. Here's what BofA Securities has to say about the newly listed stocks.

Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA

ALISO VIEJO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company, today announced that Steve Everly has joined the company as its Vice President of U.S. Sales. In this new position, Mr. Everly will lead the continued development and expansion of the company's sales organization.

RxSight, Inc. Expands Commercial Leadership with Addition of Steve Everly as Vice-President of U.S. Sales

The stock price of RxSight Inc (NASDAQ: RXST) increased 11.45%. This is why it happened.

RXST Stock Price Increased 11.45%: Why It Happened

ALISO VIEJO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the appointment of three new members to its Board of Directors effective as of the closing of the Company's initial public offering on August 3, 2021. The three appointments, including Robert (Bob) Palmisano, Robert Warner and Julie Andrews, joined directors J. Andy Corley, William J. Link, Ph.D., Juliet Tammenoms Bakker and Ron M. Kurtz, M.D. Concurrent with the new appointments, the Company announced the resignations of four long-serving board members Bruce Robertson, Ph.D., Daniel Schwartz, M.D., Christopher Cox, and Rick Wolfen.

RxSight Announces Appointments to its Board of Directors

ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight's common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.

News for RxSight Stock (RXST)